Applications in pipeline

IMMray™ technology has been developed with the aim to respond to unmet clinical needs. By deciphering serum-based biomarker signatures, it provides clinicians with actionable information. We currently have on-going projects in discovery phase targeting other cancers (e.g. prostate cancer) as well as autoimmune diseases (e.g. systemic lupus erythematosus).